Key Points
- Twist Bioscience CFO Adam Laponis sold 3,000 shares on April 14 at an average price of $55 under a pre-arranged Rule 10b5-1 plan, trimming his stake by 2.39% to 122,694 shares after prior sales in February and early April.
- Company performance and analyst stance: Twist reported a quarterly EPS miss (‑$0.50 vs. ‑$0.48) despite 16.9% revenue growth, trades near $56 with a $3.45B market cap, and carries a mixed analyst backdrop but a consensus "Moderate Buy" and $47.13 price target.
Twist Bioscience Corporation (NASDAQ:TWST - Get Free Report) CFO Adam Laponis sold 3,000 shares of Twist Bioscience stock in a transaction dated Tuesday, April 14th. The shares were sold at an average price of $55.00, for a total value of $165,000.00. Following the completion of the sale, the chief financial officer owned 122,694 shares of the company's stock, valued at $6,748,170. This trade represents a 2.39% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Adam Laponis also recently made the following trade(s):
- On Thursday, April 9th, Adam Laponis sold 2,597 shares of Twist Bioscience stock. The shares were sold at an average price of $49.89, for a total value of $129,564.33.
- On Thursday, February 12th, Adam Laponis sold 7,000 shares of Twist Bioscience stock. The shares were sold at an average price of $50.00, for a total value of $350,000.00.
Twist Bioscience Stock Down 2.4%
TWST opened at $56.23 on Friday. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.78 and a quick ratio of 3.37. The stock has a market capitalization of $3.45 billion, a price-to-earnings ratio of -43.93 and a beta of 2.20. The business has a 50-day moving average of $48.44 and a two-hundred day moving average of $38.85. Twist Bioscience Corporation has a 12 month low of $23.30 and a 12 month high of $59.90.
Twist Bioscience (NASDAQ:TWST - Get Free Report) last posted its quarterly earnings results on Monday, February 2nd. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.02). The business had revenue of $103.70 million during the quarter, compared to analysts' expectations of $100.32 million. Twist Bioscience had a negative net margin of 19.56% and a negative return on equity of 27.16%. The business's revenue for the quarter was up 16.9% on a year-over-year basis. On average, research analysts expect that Twist Bioscience Corporation will post -2.12 earnings per share for the current year.
Analysts Set New Price Targets
Several analysts have commented on TWST shares. Barclays lifted their price target on Twist Bioscience from $50.00 to $55.00 and gave the company an "overweight" rating in a report on Tuesday. TD Cowen reaffirmed a "buy" rating on shares of Twist Bioscience in a research note on Thursday, January 8th. Guggenheim lifted their price objective on Twist Bioscience from $50.00 to $55.00 and gave the company a "buy" rating in a research note on Monday, March 30th. Evercore lifted their price objective on Twist Bioscience from $42.00 to $52.00 and gave the company an "outperform" rating in a research note on Tuesday, February 3rd. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Twist Bioscience in a research note on Friday, March 27th. Seven analysts have rated the stock with a Buy rating and two have given a Sell rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $47.13.
Check Out Our Latest Research Report on TWST
Hedge Funds Weigh In On Twist Bioscience
Hedge funds and other institutional investors have recently modified their holdings of the company. Royal Bank of Canada lifted its position in Twist Bioscience by 11.8% during the 1st quarter. Royal Bank of Canada now owns 40,373 shares of the company's stock worth $1,585,000 after acquiring an additional 4,254 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Twist Bioscience by 4.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 70,310 shares of the company's stock worth $2,765,000 after acquiring an additional 3,181 shares in the last quarter. Goldman Sachs Group Inc. lifted its position in Twist Bioscience by 4.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 932,978 shares of the company's stock worth $36,629,000 after acquiring an additional 37,577 shares in the last quarter. Intech Investment Management LLC lifted its position in Twist Bioscience by 18.9% during the 1st quarter. Intech Investment Management LLC now owns 28,917 shares of the company's stock worth $1,135,000 after acquiring an additional 4,591 shares in the last quarter. Finally, Norges Bank acquired a new position in Twist Bioscience during the 2nd quarter worth approximately $737,000.
Twist Bioscience Company Profile
(
Get Free Report)
Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.
At the core of Twist's offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
